Cardiothoracic News | Medical XPRT

Showcase

Med Tech Outlook: Top Medical Ventilator Solution Providers 2021

Accurate breath analysis is key for diagnosis and assessment of pulmonary illnesses. Breath analysis is an important evaluation tool to support respiratory therapists and pulmonologists in the diagnosis and treatment of varying respiratory illnesses. Unfortunately, moisture is an impediment to successful breath analysis. Moisture in breath samples can adversely impact the accuracy of breath ...

Jun. 19, 2021

By Perma Pure LLC - a Halma Company

Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research

Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...

May 25, 2021

By Creative Enzymes

MediPines AGM100 Voted as Finalist in Medical Design Excellence Awards, MDEA 2021

We are pleased to announce that MediPines AGM100, a non-invasive pulmonary gas exchange analyzer, was selected as a finalist in the 2021 Medical Design Excellence Awards (MDEA). The MDEAs is the premier design competition in the MedTech industry organized by MD+DI and recognizes the significant achievements in medical product design and engineering that improve the quality of healthcare delivery ...

Apr. 27, 2021

By MediPines

Dutch Secretary of State visits Xeltis following RegMedXB funding

The Dutch State Secretary visited Xeltis today following the recent decision of the Government to provide funding to the RegMedXB partnership, of which Xeltis is one of the industrial partners. Minister Mona Keijzer met executives from the RegMedXB private-public partnership, which recently secured funding for up to €56 million from the Dutch National Growth Fund to build an infrastructure ...

Apr. 26, 2021

By XELTIS BV

BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices

BioStable Science & Engineering, Inc., (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair. With CE Mark approval of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable will be able to offer surgeons within the European Union a comprehensive portfolio of ...

Apr. 21, 2021

By BioStable Science & Engineering, Inc.

CEO Eliane Schutte among Top 50 Medtech CEOs

Xeltis CEO Eliane Schutte has been included in the Healthcare Technology Report’s list of 2021 Top 50 Healthcare Technology CEOs, one of only seven women featuring on the list. The Report’s list recognizes the most accomplished executives in the healthcare technology, whose leadership has been critical in developing industry leading medical devices, next generation software ...

Apr. 19, 2021

By XELTIS BV

Carmat announces the issuance of a second tranche of equity warrants within the framework of its contingent equity line with Kepler Cheuvreux

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces the issuance of a secondtranche of650,000 equity warrants within the framework of thecontingentequityline ...

Apr. 9, 2021

By Carmat

Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population. ‍ Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet ...

Apr. 8, 2021

By Benevolent

Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine

Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...

Mar. 30, 2021

By Aspect Biosystems Ltd.

AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines

AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10, ...

Mar. 29, 2021

By AVEO Pharmaceuticals, Inc.

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 ...

Mar. 29, 2021

By Eli Lilly and Company

Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper in the peer-reviewed journal Scientific Reports, describing a study into the bacterium Staphylococcus aureus (S. aureus). The paper can be accessed ...

Mar. 16, 2021

By Evaxion Biotech A/S

Xeltis CTO at FDA-led Pediatric Device Innovators Forum

Xeltis bio-restorative pulmonary heart valves and their clinical outcomes will feature at the upcoming Pediatric Device Innovators Forum organized by the U.S. Food and Drug Administration (FDA) in conjunction with five U.S. pediatric device consortia on 11 March. “I am looking forward to discussing the potential and the challenges of applying biomaterials to pediatric heart valve ...

Mar. 9, 2021

By XELTIS BV

CARMAT obtains a €1.4 million grant as part of the “Industrial recovery plan – Strategic sectors” call for projects

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that is has obtaineda €1.4 million grantas a winner of theMinistry for Industry’s ...

Mar. 9, 2021

By Carmat

Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. New real-world data will be presented evaluating SOLIRIS® (eculizumab) for the treatment of generalized myasthenia gravis (gMG) in the United ...

Mar. 4, 2021

By Alexion Pharmaceuticals, Inc.

Aidoc launches the first ai-based automated notification solution for high-risk pulmonary embolism patients

Aidoc, the leading provider of enterprise AI solutions, announced today the launch of an industry first: an AI-based automated activation solution that facilitates rapid risk assessment and care coordination for high-risk pulmonary embolism (PE) patients. Aidoc’s PE Care Coordination includes Aidoc’s FDA-cleared solution for triage and notification of PE. The solution is ...

Mar. 3, 2021

By Aidoc

Asensus Surgical Announces FDA Clearance in General Surgery

Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United ...

Mar. 3, 2021

By Asensus Surgical US, Inc.

Discover the Radio Controlled Nebulizer

Thanks to the quick-coupling tool holder plate, HERBHY can be quickly transformed into a radio-controlled nebulizer ideal for treatments to be carried out in difficult to reach areas, on slopes or inaccessible or even in the open field when it is preferable for the operator to keep away from the area the product is sprayed ...

Mar. 2, 2021

By Hymach s.r.l.

Forest Devices Announces Positive Study Results For Their Stroke Detection Technology

Medical technology pioneer Forest Devices, Inc. (FDI) today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive (LVO) strokes in emergency departments in the American Heart Association Journal, STROKE. LVOs are the type of ischemic stroke that require an interventional thrombectomy, only ...

Feb. 23, 2021

By Forest Devices

Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005

Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced positive interim safety, protein expression and biomarker data from the ongoing open-label Phase I/II FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Interim results ...

Feb. 12, 2021

By Gyroscope Therapeutics Limited